Form 4 for MRNA Moderna
Accepted 2021-11-09 00:00:00 ET · period of report 2021-11-05 · accession 0001127602-21-028715 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-09 | 2021-11-05+ | MRNA | Andres Juan | See remarks | M - OptEx | $13.21 | +20.0K | 5,000 | New | +$264.3K |
| DM | 2021-11-09 | 2021-11-05+ | MRNA | Andres Juan | See remarks | S - Sale+OE | $234.85 | -20.0K | 0 | -100% | -$4.70M |
| DM | 2021-11-09 | 2021-11-05+ | MRNA | Andres Juan | See remarks | M - OptEx | $0.00 | -20.0K | 58.6K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-08 | M | A | 10,000 | $14.22 | 10,000 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-08 | M | A | 5,000 | $12.21 | 15,000 | D | — | — | |
| 3 | Common | Common Stock | 2021-11-05 | S | D | 5,000 | $240.00 | 0 | D | — | — | |
| 4 | Common | Common Stock | 2021-11-05 | M | A | 5,000 | $12.21 | 5,000 | D | — | — | |
| 5 | Common | Common Stock | 2021-11-08 | S | D | 15,000 | $233.13 | 0 | D | — | — | |
| 6 | Derivative | Stock Option (Right to Buy) | 2021-11-05 | M | D | 5,000 | $0.00 | 120,000 | D | $12.21 · — to 2027-08-29 | 5,000 Common Stock | (F2) This option is fully vested and exercisable. |
| 7 | Derivative | Stock Option (Right to Buy) | 2021-11-08 | M | D | 5,000 | $0.00 | 115,000 | D | $12.21 · — to 2027-08-29 | 5,000 Common Stock | (F2) This option is fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2021-11-08 | M | D | 10,000 | $0.00 | 58,629 | D | $14.22 · — to 2028-02-28 | 10,000 Common Stock | (F3) 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. |